Summary of the invention:
The object of the present invention is to provide the active component of Radix Morindae Officinalis.
Another object of the present invention is to provide the method for preparing of above-mentioned effective component of morinda officinalis.
The present invention also provides the preparation that contains above-mentioned effective component of morinda officinalis and the purposes of this component.
Effective component of morinda officinalis of the present invention, its preparation process may further comprise the steps:
Step 1: Radix Morindae Officinalis is extracted as solvent with ethyl acetate and alcohol mixture,
Step 2: medicinal residues are used ethanol extraction, obtain extracting solution,
Step 3: extracting solution gets eluent through column chromatography.
Step 4: with the eluent that the preparative liquid chromatography gradient elution obtains, mobile phase is water and acetonitrile, collects 28.0-32.0 minute, a 52.0-56.0 minute eluent and obtains active component 1 (or being called B07), active component 2 (or being called B13).
Wherein ethyl acetate described in the step 1 and alcoholic acid mixture, both ratios are ethyl acetate: ethanol=1-5: 1-5, are preferably ethyl acetate: ethanol=1-2: 1-2 most preferably is ethyl acetate: ethanol=1: 1.
In the said step, step 1 is specially: getting the Radix Morindae Officinalis medical material, is solvent with ethyl acetate: ethanol=1-5: 1-5, and reflux, extract, is separated extracting solution with medicinal residues,
Step 2 is specially: medicinal residues obtain extracting solution with the ethanol extraction of 50-90%,
Step 3 is specially: above extracting solution is crossed the ODS-C18 post with appearance on 5% dissolve with ethanol, at first, adopts 5% ethanol as mobile phase, changes 50% ethanol then as mobile phase, gets eluent,
Step 4 is specially: continue to separate the eluent that obtains with preparative liquid chromatography, mobile phase is water-A and acetonitrile-B, carries out gradient elution, and said gradient elution program is following:
Table 1: gradient elution table
Flow velocity is 10ml/min, and column temperature is a room temperature; Sample is used 100% dissolve with ethanol, separates through preparative liquid chromatography, collects 28.0-32.0 minute or 52.0-56.0 minute solution in the time period, and solution obtains active component behind concentrate drying.
The preferred effective component of morinda officinalis method for preparing of the present invention comprises the following steps: the Radix Morindae Officinalis pulverizing, adds 6-10 and doubly measures ethyl acetate: ethanol=1: 1, reflux 1-2 hour; Extract 1-3 time, medicinal residues add 6-10 and doubly measure 50-90% ethanol, reflux, filtrating merge extracting solution; After extracting solution concentrated, with appearance on 5% dissolve with ethanol, mistake ODS-C18 post; At first, adopt 5% ethanol, change 50% ethanol then as mobile phase as mobile phase; Get eluent, continue separation eluent with preparative liquid chromatography, separation condition is: chromatographic column is Agilent preparative column (Zorbax SB-C18; 21.2mm * 250mm), mobile phase is water A and acetonitrile B, the gradient elution program is following:
Flow velocity is 10ml/min, and column temperature is a room temperature; Sample is used 100% dissolve with ethanol, separates through preparative liquid chromatography, collects solution at time period 28.0-32.0 minute or 52.0-56.0 minute, and solution obtains active component behind concentrate drying.
The most preferred effective component of morinda officinalis method for preparing of the present invention comprises the following steps:
Radix Morindae Officinalis is pulverized, and adds 8 times of amount ethyl acetate: ethanol=1: 1, and reflux 1 hour is extracted 2 times; Medicinal residues add 8 times of amount 70% ethanol, and reflux 1 hour is extracted 2 times, filtrate merge extracting solution; After extracting solution concentrated, with appearance on 5% dissolve with ethanol, mistake ODS-C18 post; At first, adopt 1250ml 5% ethanol, change 1250ml 50% ethanol then as mobile phase as mobile phase; Get eluent, continue separation eluent with preparative liquid chromatography, separation condition: chromatographic column is Agilent preparative column (Zorbax SB-C18; 21.2mm * 250mm), mobile phase is water A and acetonitrile B, the gradient elution program is following
Flow velocity is 10ml/min, and column temperature is a room temperature; Sample is used 100% dissolve with ethanol, separates through preparative liquid chromatography, collects solution at time period 28.0-32.0 minute or 52.0-56.0 minute, and solution obtains active component behind concentrate drying.
The present invention also provides the pharmaceutical composition that is prepared into as active constituents of medicine with Chinese medicine active component of the present invention, and pharmaceutical composition of the present invention comprises active component, and said composition can also add the medicine acceptable carrier as required.
Compositions of the present invention is the pharmaceutical dosage forms of UD, and said unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Compositions of the present invention active component wherein, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.
Compositions of the present invention obtains through above-mentioned active component and medicine acceptable carrier are mixed with.
Compositions of the present invention; Its pharmaceutical dosage forms can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.
Compositions of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill through mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive; Such as suspending agent; For example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat; Emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, can this chemical compound be suspended or dissolving.The preparation of solution is normally through being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Compositions of the present invention; When being prepared into medicament, optionally add suitable medicine acceptable carrier; Said medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Compositions of the present invention is confirmed usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
The present invention also provides the application at anti-tumor aspect of Chinese medicine active component of the present invention and pharmaceutical composition.Below be the data of pharmacological evaluation:
Screening active ingredients
Cell strain: HL-60 tumor cell
Cell culture and kind plate cell culture: use RPMI 1640 (Gibco) [adding the 2g/L sodium bicarbonate] 90%, hyclone (Ilex purpurea Hassk.[I.chinensis Sims) 10% Mixed culture HL 60 cells, density need be lower than 106/mL.Calculating needs cell total amount NT=ρ cellmL-1 * VT (ρ=2 * 104/mL), wherein VT=0.1mL * hole count+cell groove surplus.Suspension cell on the piping and druming culture bottle wall adds in the centrifuge tube.Get 10 μ L, add the blue dilution of 10 μ L Placenta Hominiss, viable count sum NL on the count plate, then the cell number N in the centrifuge tube is: NL/4 * 104 * 2 * V, wherein V is the liquor capacity in the centrifugal preceding centrifuge tube.It is centrifugal that (900rad/min 10min), inhales and removes supernatant, adds culture fluid V1mL, and piping and druming makes the cell mixing, draws V2mL and joins in the cell groove, makes V2=NT/N * V1.The culture fluid that in the cell groove, adds VT-V2mL again with volley of rifle fire piping and druming, mixing, is got this liquid, and every hole adds 150 μ L.Choose 4 holes behind the kind plate and add 200 μ L culture fluid as blank, the residue hole adds 200 μ L PBS, to reduce the evaporation of culture fluid.
The dosage regimen effective component of morinda officinalis adds the DMSO dissolving of respective volume, and concentration is about 50mg/mL.The concussion dissolving, if there are a large amount of drops to glue wall, can be suitably centrifugal.Can store-20 ℃.The culture fluid that in 96 new orifice plates, adds 220 μ L/ holes will be drawn 0.88 μ L medicinal liquid and add mixing, dilute 250 times, and the medicine that above-mentioned dilution is good has every hole, hole of cell to add 50 μ L to kind, and this moment, drug dilution was 1000 times, and promptly final concentration is 50ng/mL.Hatch 48h.Each concentration is established 4 parallel multiple holes, and every plate is established negative control group (add blank solution in the cell, blank solution is joined method---add the culture fluid of 200 μ L, will draw 0.88 μ LDMSO and add mixing), reaches positive controls (cisplatin final concentration 4 μ g/mL).SRB dyeing: after cell culture finishes, take out culture plate, every hole adds trichloroacetic acid (TCA) the 100 μ L fixed cells of 40% (mass/volume), and room temperature is placed 5min, places 1h in 4 ℃ of refrigerators.Each hole of culture plate is with deionized water wash 5 times, to remove TCA.Behind air drying, every hole adds 0.4% SRB100 μ L (dissolving of 1% chromatographically pure acetic acid), room temperature held 20min; Discard in each hole and wash 5 times with 1% acetic acid behind the liquid; Remove unconjugated dyestuff, with the dissolving of 10mmol/L Tris150 μ L/ hole, 5min vibrates behind the air drying; Use ELIASA (ELx 800) to measure, used wavelength is 490nm.The calculating suppression ratio of suppression ratio calculates by following formula:
Drug effect result sees table 2.Table 2
|
Radix Morindae Officinalis B07 component |
Negative |
Blank |
Positive |
Average cell survival number |
0.10 |
0.35 |
0.05 |
0.11 |
Suppression ratio (%) |
83.00 |
0 |
100 |
79.42 |
RSD(%) |
1.40 |
3.42 |
2.58 |
1.98 |
|
Radix Morindae Officinalis B13 component |
Negative |
Blank |
Positive |
Average cell survival number |
0.11 |
0.35 |
0.05 |
0.11 |
Suppression ratio (%) |
80.50 |
0 |
100 |
79.42 |
RSD(%) |
9.78 |
3.42 |
2.58 |
1.98 |
Cell strain: Hep G2 tumor cell
Cell culture and kind plate cell culture: use DMEM high glycoform (Gibco) [adding the 3.7g/L sodium bicarbonate] 90%, hyclone (Ilex purpurea Hassk.[I.chinensis Sims) 10%, non essential amino acid (Gibco) 1% Mixed culture Hep G2 cell.Calculating needs cell total amount NT=ρ cellmL-1 * VT (ρ=2 * 103/mL), wherein VT=0.1mL * hole count+cell groove surplus.Suspension cell on the piping and druming culture bottle wall adds in the centrifuge tube.Get 10 μ L, add the blue dilution of 10 μ L Placenta Hominiss, viable count sum NL on the count plate, then the cell number N in the centrifuge tube is: NL/4 * 104 * 2 * V, wherein V is the liquor capacity in the centrifugal preceding centrifuge tube.It is centrifugal that (900rad/min 10min), inhales and removes supernatant, adds culture fluid V1mL, and piping and druming makes the cell mixing, draws V2mL and joins in the cell groove, makes V2=NT/N * V1.The culture fluid that in the cell groove, adds VT-V2mL again with volley of rifle fire piping and druming, mixing, is got this liquid, and every hole adds 100 μ L, hatches 24h.Choose 4 holes adding culture fluid as blank after planting plate, the residue hole adds 100 μ L PBS, to reduce the evaporation of culture fluid.
The dosage regimen effective component of morinda officinalis is according to the weight of the medicine of institute's weighing, according to the weight of the medicine of institute's weighing, adds the DMSO dissolving of respective volume, and concentration is about 50mg/mL.The concussion dissolving, if there are a large amount of drops to glue wall, can be suitably centrifugal.Can store-20 ℃.96 orifice plates change liquid, and every hole adds fresh medium 150 μ L.The culture fluid that in 96 new orifice plates, adds 220 μ L/ holes will be drawn 0.88 μ L medicinal liquid and add mixing, dilute 250 times, and the medicine that above-mentioned dilution is good has every hole, hole of cell to add 50 μ L to kind, and this moment, drug dilution was 1000 times, and promptly final concentration is 50 μ g/mL.Hatch 48h.Each concentration is established 4 (2) individual parallel multiple holes, and every plate is established negative control group (add blank solution in the cell, blank solution is joined method---add the culture fluid of 200 μ L, will draw 0.88 μ LDMSO adding mixing), positive controls (amycin final concentration 4 μ g/mL).The MTT colorimetric method for determining: take out culture plate, every hole, place to go supernatant, adding culture fluid-MTT mixed solution (culture fluid: 100 μ L MTT solution=10: 1), hatch 4h.Culture fluid is abandoned in suction, and every hole adds the DMSO of 150 μ L, vibration 10min, and 550nm ELIASA (Elx800) is measured.
The calculating suppression ratio of suppression ratio calculates by following formula:
Drug effect result sees table 3.
Table 3
|
Radix Morindae Officinalis B07 component |
Negative |
Blank |
Positive |
Average cell survival number |
0.39 |
0.59 |
0.16 |
0.17 |
Suppression ratio (%) |
47.67 |
0 |
100 |
96.86 |
RSD(%) |
8.45 |
4.861 |
5.093 |
5.272 |
|
Radix Morindae Officinalis B13 component |
Negative |
Blank |
Positive |
Average cell survival number |
0.37 |
0.59 |
0.16 |
0.17 |
Suppression ratio (%) |
51.51 |
0 |
100 |
96.86 |
RSD(%) |
7.87 |
4.861 |
5.093 |
5.272 |
Cell strain: K562 tumor cell
Cell culture and kind plate cell culture: use RPMI 1640 (Gibco) [adding the 2g/L sodium bicarbonate] 90%, calf serum (match is happy) 10%, non essential amino acid (Gibco) 1% Mixed culture K 562 cells.Calculating needs cell total amount NT=ρ cellmL-1 * VT (ρ=8 * 103/mL), wherein VT=0.1mL * hole count+cell groove surplus.Suspension cell on the piping and druming culture bottle wall adds in the centrifuge tube.Get 10 μ L, add the blue dilution of 10 μ L Placenta Hominiss, viable count sum NL on the count plate, then the cell number N in the centrifuge tube is: NL/4 * 104 * 2 * V, wherein V is the liquor capacity in the centrifugal preceding centrifuge tube.It is centrifugal that (900rad/min 10min), inhales and removes supernatant, adds culture fluid V1mL, and piping and druming makes the cell mixing, draws V2mL and joins in the cell groove, makes V2=NT/N * V1.The culture fluid that in the cell groove, adds VT-V2mL again with volley of rifle fire piping and druming, mixing, is got this liquid, and every hole adds 100 μ L, hatches 24h.Choose 4 holes adding culture fluid as blank after planting plate, the residue hole adds 100 μ L PBS, to reduce the evaporation of culture fluid.
The dosage regimen effective component of morinda officinalis adds the DMSO dissolving of respective volume, and concentration is about 50mg/mL.The concussion dissolving, if there are a large amount of drops to glue wall, can be suitably centrifugal.Can store-20 ℃.96 orifice plates change liquid, and every hole adds fresh medium 150 μ L.The culture fluid that in 96 new orifice plates, adds 220 μ L/ holes will be drawn 0.88 μ L medicinal liquid and add mixing, dilute 250 times, and the medicine that above-mentioned dilution is good has every hole, hole of cell to add 50 μ L to kind, and this moment, drug dilution was 1000 times, and promptly final concentration is 50 μ g/mL.Hatch 48h.Each concentration is established 4 (2) individual parallel multiple holes, and every plate is established negative control group (add blank solution in the cell, blank solution is joined method---add the culture fluid of 200 μ L, will draw 0.88 μ LDMSO adding mixing), positive controls (amycin final concentration 4 μ g/mL).SRB dyeing: after cell culture finishes, take out culture plate, every hole adds trichloroacetic acid (TCA) the 70 μ L fixed cells of 40% (mass/volume), places 1h in 4 ℃ of refrigerators.Each hole of culture plate is with deionized water wash 5 times, to remove TCA.Behind air drying, every hole adds 0.4% SRB100 μ L (dissolving of 1% chromatographically pure acetic acid), room temperature held 20min; Discard in each hole and wash 5 times with 1% acetic acid behind the liquid; Remove unconjugated dyestuff, with the dissolving of 10mmol/L Tris150 μ L/ hole, 5min vibrates behind the air drying; Use ELIASA (ELx800) to measure, used wavelength is 490nm.
The calculating suppression ratio of suppression ratio calculates by following formula:
Drug effect result sees table 4.
Table 4
|
Radix Morindae Officinalis B07 component |
Negative |
Blank |
Positive |
Average cell survival number |
0.13 |
0.69 |
0.04 |
0.12 |
Suppression ratio (%) |
85.54 |
0 |
100 |
87.19 |
RSD(%) |
3.17 |
6.622 |
1.33 |
4.363 |
|
Radix Morindae Officinalis B13 component |
Negative |
Blank |
Positive |
Average cell survival number |
0.16 |
0.69 |
0.04 |
0.12 |
Suppression ratio (%) |
81.15 |
0 |
100 |
87.19 |
RSD(%) |
4.79 |
6.622 |
1.33 |
4.363 |
Beneficial effect of the present invention is:
1. use the reverse phase silica gel post in the extraction and separation process of the present invention, can remove the impurity that chlorophyll etc. is prone on the preparative hplc post, form dead absorption effectively, improved content of effective, can obtain effective ingredient fast and accurately.
2. effective component of morinda officinalis chemical constituent provided by the invention is simply clear and definite, on pharmacological research, is easier to illustrate its mechanism of action, is easier to the quality control of medicine aborning.
Method provided by the invention obtains containing B07 first from the Radix Morindae Officinalis medical material, the B13 active component, and first it is carried out medicine efficacy screening on various tumor cell strains; Because composition is definite, content is clear and definite, and preparation technology is convenient; Active good, the suitable antitumor new Chinese medicine that is developed to.
The specific embodiment
To combine embodiments of the invention further explain flesh and blood of the present invention below, this embodiment only is used to the present invention is described and the present invention is not limited.
The preparation of embodiment 1 effective component of morinda officinalis
Radix Morindae Officinalis is pulverized, and pulverizes the back and crosses 20 mesh sieves, adds 8 times of amount ethyl acetate: ethanol=1: 1, reflux 1 hour; Extract 2 times, medicinal residues add 8 times of amount 70% ethanol, and reflux 1 hour is extracted 2 times; Filtrating merge extracting solution, after extracting solution concentrated, with appearance on 5% dissolve with ethanol, mistake ODS-C18 post; At first, adopt 1250ml 5% ethanol, change 1250ml 50% ethanol then as mobile phase as mobile phase; Get eluent, continue separation eluent with preparative liquid chromatography, separation condition: chromatographic column is Agilent preparative column (ZorbaxSB-C18; 21.2mm * 250mm), mobile phase is water A and acetonitrile B, the gradient elution program is following
Flow velocity is 10ml/min, and column temperature is a room temperature; Sample is used 100% dissolve with ethanol, separates through preparative liquid chromatography, collects solution at time period 28.0-32.0 minute or 52.0-56.0 minute, and solution obtains active component behind concentrate drying.
The analysis of embodiment 2 effective component of morinda officinalis
Chromatographic conditionChromatographic column Agilent Zorbax SB-C18 post (4.6mm * 150mm, 5 μ m); Adopt gradient elution, mobile phase A is 0.2% glacial acetic acid aqueous solution mutually, and Mobile phase B is mutually for containing the acetonitrile solution of 0.2% glacial acetic acid; The gradient elution program is following: in the time of 0 minute, mobile phase A is that 90% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile solution of 10% 0.2% glacial acetic acid; In the time of 10 minutes, mobile phase A is that 50% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile solution of 50% 0.2% glacial acetic acid; In the time of 30 minutes, mobile phase A is that 5% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile solution of 95% 0.2% glacial acetic acid; In the time of 35 minutes, mobile phase A is that 5% 0.2% glacial acetic acid aqueous solution, Mobile phase B are the acetonitrile of 95% 0.2% glacial acetic acid.Solution flow rate 0.5mLmin
-1It is long to detect the wavelength all-wave; 30 ℃ of column temperatures; ELSD condition: 105 ℃ of drift tube temperatures; Nitrogen flow rate 2.0L/min
The preparation of need testing solutionTake by weighing active component of the present invention, in volumetric flask, be diluted to scale, shake up, promptly get with dissolve with methanol solution.
Assay methodThe accurate need testing solution of drawing injects chromatograph of liquid, measures.
Embodiment 3 effective component of morinda officinalis preparations
Get the effective component of morinda officinalis 1 or 2 of embodiment 1,0.5g and 10.5g Polyethylene Glycol-6000 mix homogeneously, heating and melting moves in the drop pill drip irrigation behind the change material, and medicine liquid droplet is to 6-8 ℃ of liquid paraffin, and oil removing makes 400 of drop pill.
Embodiment 4 effective component of morinda officinalis preparations
Get the effective component of morinda officinalis 1 or 2 of embodiment 1,0.5g, glucose 4.5g, sodium thiosulfate 0.9g and distilled water 1ml, behind the said components mix homogeneously, lyophilization, 500 of packing promptly get.
Embodiment 5 effective component of morinda officinalis preparations
Get Lignum Dalbergiae Odoriferae oil 1.5g, join in the saturated hydroxypropyl of 13ml, stirring and dissolving filters, the filter leaf cold drying, Lignum Dalbergiae Odoriferae oil and the clathrate powder of hydroxypropyl.Except that above-mentioned Lignum Dalbergiae Odoriferae oil closes the clathrate powder of hydroxypropyl, get the effective component of morinda officinalis of embodiment 1 again, 0.5g, mannitol 5.5g, calcium disodium edetate 0.9g and distilled water 2ml, behind the said components mixing, lyophilization, 300 of packing promptly get.